Have a feature idea you'd love to see implemented?
Let us know!
TRAW Traws Pharma Inc.
Price (delayed)
$4.51
Market cap
$13.65M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$141.56
Enterprise value
$8.24M
onconova therapeutics, inc. (nasdaq: ontx) is a clinical-stage biopharmaceutical company focused on discovering and developing novel small molecule drug candidates to treat cancer. using a proprietary chemistry platform, onconova has
Highlights
The equity has dropped by 114% year-on-year but it has surged by 98% since the previous quarter
The quick ratio has dropped by 75% year-on-year and by 62% since the previous quarter
Traws Pharma's net income has decreased by 2.7% from the previous quarter
Key stats
What are the main financial stats of TRAW
Market
Valuations
Earnings
Shares outstanding
3.03M
Market cap
$13.65M
Enterprise value
$8.24M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
19.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.44
Revenue
$226,000
EBIT
-$140.79M
EBITDA
-$140.77M
Free cash flow
-$30.18M
Per share
Balance sheet
Liquidity
EPS
-$141.56
Free cash flow per share
-$31.39
Book value per share
-$2.01
Revenue per share
$0.24
TBVPS
$9.29
Total assets
$8.94M
Total liabilities
$10.97M
Debt
$0
Equity
-$2.03M
Working capital
$575,000
Debt to equity
0
Current ratio
1.07
Quick ratio
0.65
Net debt/EBITDA
0.04
Margins
Efficiency
Dividend
EBITDA margin
-62,288.1%
Gross margin
100%
Net margin
-62,294.2%
Operating margin
-62,636.3%
Return on assets
-822.4%
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
-23,943%
Return on sales
-62,294.2%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
TRAW stock price
How has the Traws Pharma stock price performed over time
Intraday
0.45%
1 week
-19.19%
1 month
-3.01%
1 year
-71.81%
YTD
-75.8%
QTD
-23.3%
Financial performance
How have Traws Pharma's revenue and profit performed over time
Revenue
$226,000
Gross profit
$226,000
Operating income
-$141.56M
Net income
-$140.79M
Gross margin
100%
Net margin
-62,294.2%
Traws Pharma's net income has decreased by 2.7% from the previous quarter
The net margin has contracted by 2.7% from the previous quarter
The company's operating income fell by 2.5% QoQ
Traws Pharma's operating margin has decreased by 2.5% from the previous quarter
Growth
What is Traws Pharma's growth rate over time
Valuation
What is Traws Pharma stock price valuation
P/E
N/A
P/B
N/A
P/S
19.19
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
36.44
The EPS has contracted by 2.3% from the previous quarter
The equity has dropped by 114% year-on-year but it has surged by 98% since the previous quarter
The price to sales (P/S) is 90% lower than the 5-year quarterly average of 193.6 and 68% lower than the last 4 quarters average of 59.6
Efficiency
How efficient is Traws Pharma business performance
TRAW's return on assets is down by 30% since the previous quarter
The ROS has contracted by 2.7% from the previous quarter
Dividends
What is TRAW's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for TRAW.
Financial health
How did Traws Pharma financials performed over time
TRAW's total assets is 19% smaller than its total liabilities
The quick ratio has dropped by 75% year-on-year and by 62% since the previous quarter
TRAW's total assets has dropped by 67% year-on-year and by 52% since the previous quarter
The debt is 100% more than the equity
The equity has dropped by 114% year-on-year but it has surged by 98% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.